In vitro evaluation of the monoclonal antibody 64Cu-IgG M75 against human carbonic anhydrase IX and its in vivo imaging

Čepa, Adam; Ráliš, J.; Král, Vlastimil; Paúrová, Monika; Kučka, Jan; Humajová, Jana; Lázníček, Milan; Lebeda, O.

doi:10.1016/j.apradiso.2017.12.013

Cited by 11 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M75, another mAb targeting CAIX, is regularly used in IHC studies to detect CAIX . In recent studies this mAb has been radiolabeled with 64 Cu and 61 Cu, and the developed radiotracers revealed specific binding in CAIX-expressing colorectal cancer models. , Moreover, several other CAIX targeting mAbs have shown preliminary anticancer effects. − Up to now, they have not been used for immunoPET imaging. Lastly, it is worthwhile to note that CAIX is highly expressed in a plethora of other tumor cells, tumor-associated stromal cells, and cancer stem cells .…”

Section: Immunopet Imaging Of Cancersmentioning

confidence: 99%

“…677 In recent studies this mAb has been radiolabeled with 64 Cu and 61 Cu, and the developed radiotracers revealed specific binding in CAIX-expressing colorectal cancer models. 678,679 Moreover, several other CAIX targeting mAbs have shown preliminary anticancer effects. 680−682 Up to now, they have not been used for immunoPET imaging.…”

Section: Carbonic Anhydrase IXmentioning

confidence: 99%

See 1 more Smart Citation

ImmunoPET: Concept, Design, and Applications

et al. 2020

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a paradigmshifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89 Zr-Df-pertuzumab and 89 Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.

show abstract

Section: Immunopet Imaging Of Cancersmentioning

confidence: 99%

Section: Carbonic Anhydrase IXmentioning

confidence: 99%

ImmunoPET: Concept, Design, and Applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…There are other factors involved in tumor development, progression, and poor prognosis in colorectal cancer, assessed as targets for immunoPET in preclinical studies for the detection of colorectal cancer cell lines, including HER3 ( 69 ), angiogenesis factors [VEGFR ( 161 ) and PDGFRβ ( 82 )], and hypoxia (M75 targeting carbonic anhydrase-IX [CA-IX]) ( 40 , 207 ).…”

Section: Immunopet In Different Malignanciesmentioning

confidence: 99%

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

et al. 2022

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target a broad spectrum of molecules expressed by malignant cells or tumor microenvironments. Only a few are translated into clinical studies and barely into clinical practices. Some drawbacks include slow radioimmunotracer kinetics, high physiologic uptake in lymphoid organs, and heterogeneous activity in tumoral lesions. Measures are taken to overcome the disadvantages, and new tracers are being developed. In this review, we aim to mention the fundamental components of immunoPET imaging, explore the groundbreaking success achieved using this new technique, and review different radioimmunotracers employed in various solid tumors to elaborate on this relatively new imaging modality.

show abstract

“…Copper offers well‐established coordination chemistry which allows the use of various chelators, such as DiamSar, NOTA, NODA‐GA, PCTA and their derivatives . Using chelator‐conjugated antibodies, 64 Cu has been investigated in studies against pancreatic cancer, malignant lymphoma, breast cancer, and carbonic anhydrase (CA) IX expressing malignant tissue . Antibody fragments (Fab and F(ab) 2 ), also radiolabelled with 64 Cu via chelators, have been used in studies against ovarian cancer, breast cancer, and head and neck cancer .…”

Section: Introductionmentioning

confidence: 99%

Fully Automated Production and Characterization of ⁶⁴Cu and Proof‐of‐Principle Small‐Animal PET Imaging Using ⁶⁴Cu‐Labelled CA XII Targeting 6A10 Fab

et al. 2018

View full text Add to dashboard Cite

Cu is a cyclotron-produced radionuclide which offers, thanks to its characteristic decay scheme, the possibility of combining positron emission tomography (PET) investigations with radiotherapy. We evaluated the Alceo system from Comecer SpA to automatically produce Cu for radiolabelling purposes. We established a Cu production routine with high yields and radionuclide purity in combination with excellent operator radiation protection. The carbonic anhydrase XII targeting 6A10 antibody Fab fragment was successfully radiolabelled with the produced Cu, and proof-of-principle small-animal PET experiments on mice bearing glioma xenografts were performed. We obtained a high tumor-to-contralateral muscle ratio, which encourages further in vivo investigations of the radioconjugate regarding a possible application in diagnostic tumor imaging.

show abstract

In vitro evaluation of the monoclonal antibody 64Cu-IgG M75 against human carbonic anhydrase IX and its in vivo imaging

Cited by 11 publications

References 24 publications

ImmunoPET: Concept, Design, and Applications

ImmunoPET: Concept, Design, and Applications

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Fully Automated Production and Characterization of ⁶⁴Cu and Proof‐of‐Principle Small‐Animal PET Imaging Using ⁶⁴Cu‐Labelled CA XII Targeting 6A10 Fab

Contact Info

Product

Resources

About

In vitro evaluation of the monoclonal antibody 64Cu-IgG M75 against human carbonic anhydrase IX and its in vivo imaging

Cited by 11 publications

References 24 publications

ImmunoPET: Concept, Design, and Applications

ImmunoPET: Concept, Design, and Applications

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Fully Automated Production and Characterization of 64Cu and Proof‐of‐Principle Small‐Animal PET Imaging Using 64Cu‐Labelled CA XII Targeting 6A10 Fab

Contact Info

Product

Resources

About

Fully Automated Production and Characterization of ⁶⁴Cu and Proof‐of‐Principle Small‐Animal PET Imaging Using ⁶⁴Cu‐Labelled CA XII Targeting 6A10 Fab